| Rheopheresis |
 |
 |
 Share
Rheopheresis is still an unproven therapy for dry macular degeneration. In clinical trials, it was shown to be a safe procedure but the visual results were not conclusive.
The U.S. Clinical Trial was terminated by the sponsor for lack of funding. It is still available in Canada and Germany.
Rheopheresis is similar to kidney dialysis. The patient’s blood is removed from one arm, passed through a filter, and returned to the other arm. Rheopheresis removes substances termed "vascular risk factors" that accumulate in the blood of some patients. These include substances like LDL cholesterol, fibrinogen and lipoprotein A. Recent evidence supports the idea that AMD may arise from mechanisms associated with poor blood flow in retinal blood vessels. In addition, new studies have shown that AMD progression may be related to the presence of elevated blood levels of certain vascular risk factors. Rheopheresis reduces these substances in the blood to promote an improvement in blood flow and vascular function in the retina and elsewhere. |
Search
Get News!
SIGN UP NOW
To receive the "AMD Update" and keep up-to-date with the latest research & treatment options:
For Email Newsletters you can trust